Vascular endothelial growth factor or VEGF is a signalling protein which boosts the development of new blood vessels. VEGF forms a portion of the mechanism which restores the blood flow to cells when they're deprived of blood because of compromised blood flow.
This protein also stimulates the development of new blood vessels following trauma as well as the rise of muscle following exercise was performed. VEGF also boosts the introduction of new blood vessels to bypass cells. The Human VEGF ELISA equipment is an enzyme-linked immunosorbent kit used for the quantitative measurement of human VEGF in serum, plasma, cells and urine.
Human VEGF ELISA Kit was used to quantify VEGFA amounts in human umbilical vascular endothelial cells (HUVECs) incubated with plasma in pre-eclamptic and healthy elderly women. Individual VEGF-A ELISA Kit has been utilized to qualify VEGF in human liver, residual cytokines at decellularized meningeal scaffolds, human varicose veins fibroblasts etc.
It stimulates migration and proliferation of endothelial cells. VEGF induces microvascular permeability by improving function of vesicular-vacuolar organelle VEGF plays a very prominent role in both normal and pathological angiogenesis. Substantial evidence indicates that VEGF is involved in the induction of tumor metastasis and intraocular neo-vascular syndromes.
Increased expression of VEGF causes retinal angiogenesis, thus, inhibition of VEGF utilizing soluble VEGF-receptor chimeric proteins may be thought of as a possible treatment for ischemic retinal disease. Modified expression of VEGF can also be related to rheumatoid arthritis, Graves' disease, psoriasis, cardiovascular disease, and peripheral limb disorder.